Spain Cancer Diagnostics Market Size & Outlook, 2023-2030
Spain cancer diagnostics market, 2018-2030 (US$M)
Related Markets
Spain cancer diagnostics market highlights
- The Spain cancer diagnostics market generated a revenue of USD 2,459.4 million in 2023 and is expected to reach USD 3,615.9 million by 2030.
- The Spain market is expected to grow at a CAGR of 5.7% from 2024 to 2030.
- In terms of segment, consumables was the largest revenue generating product in 2023.
- Consumables is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer diagnostics market data book summary
| Market revenue in 2023 | USD 2,459.4 million |
| Market revenue in 2030 | USD 3,615.9 million |
| Growth rate | 5.7% (CAGR from 2023 to 2030) |
| Largest segment | Consumables |
| Fastest growing segment | Consumables |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Services, Instruments, Consumables |
| Key market players worldwide | Abbott Laboratories, Roche Holding AG, GE HealthCare Technologies Inc Common Stock, Qiagen NV, Becton Dickinson & Co, Koninklijke Philips NV, Siemens Healthineers AG ADR, Hologic Inc, Thermo Fisher Scientific Inc, Illumina Inc |
Other key industry trends
- In terms of revenue, Spain accounted for 2.3% of the global cancer diagnostics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 9,637.9 million by 2030.
Consumables was the largest segment with a revenue share of 60.03% in 2023. Horizon Databook has segmented the Spain cancer diagnostics market based on services, instruments, consumables covering the revenue growth of each sub-segment from 2018 to 2030.
Spain’s biotechnology industry is rapidly growing, owing primarily to the increasing maturity of biotechnology startups. In addition, international investments continue to increase in the country. This is anticipated to positively impact revenue generation in the market by increasing the local adoption of MCED tests.
In May 2020, the first trial on the early screening of colorectal cancer was launched in Catalonia. The objective of the pilot project was to determine whether early detection might reduce morbidity related to cancer. In 2021, The Spanish Society of Medical Oncology awarded two grants to projects at Hospital del Mar and the Hospital del Mar Medical Research Institute (IMIM).
One project, led by Dr. Laura Visa, focused on the utility of new serum oncometabolites for the early diagnosis, treatment response prediction, and prognosis of gastric cancer. This project aimed to identify serum biomarkers for the early diagnosis of gastric cancer and assess their utility as predictive & prognostic markers for the disease. The project received a USD 21,400 grant for 2 years and would be conducted in collaboration with the Applied Metabolomics Research Group at IMIM.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Diagnostics Market Scope
Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Spain cancer diagnostics market size, by product, 2018-2030 (US$M)
Spain Cancer Diagnostics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
